Definium Therapeutics, Inc. (formerly MindMed) (DFTX) — Mind Medicine (MindMed) relaunched as Definium Therapeutics, a new corporate name and brand identity meant to distance the company from its 2021 'shroom-stock' vintage and reframe it as a rigorous late-stage psychiatry developer.
Management emphasized a pipeline led by DT120 ODT (its optimized LSD/lysergide tartrate), with three Phase 3 readouts across major depressive disorder and generalized anxiety disorder expected during 2026. The move made Definium the second advanced psychedelic drug developer to rebrand in early 2026, after Cybin became Helus Pharma days earlier.
Source: finance.yahoo.com
For the rest of that week's sector news, read our week in review.